Share Name Share Symbol Market Type Share ISIN Share Description
Bayer Ord LSE:BYR London Ordinary Share DE000BAY0017 REG SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00 € +0.00% 55.93 € 0.00 € 0.00 € - - - 0 06:30:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 35,088.0 1,721.0 170.0 32.9 42,749.24

Bayer Ord (BYR) Latest News

Real-Time news about Bayer Ord (London Stock Exchange): 0 recent articles
More Bayer Ord News
Bayer Ord Takeover Rumours

Bayer Ord (BYR) Share Charts

1 Year Bayer Ord Chart

1 Year Bayer Ord Chart

1 Month Bayer Ord Chart

1 Month Bayer Ord Chart

Intraday Bayer Ord Chart

Intraday Bayer Ord Chart

Bayer Ord (BYR) Discussions and Chat

Bayer Ord Forums and Chat

Date Time Title Posts
16/10/200809:12A Buyer for BAYER25
28/10/200120:23ANTHRAX - Bayer AG manufacture Cipro15

Add a New Thread

Bayer Ord (BYR) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Bayer Ord trades in real-time

Bayer Ord (BYR) Top Chat Posts

grupo guitarlumber: Bayer "overweight," target price raised Friday, October 26, 2007 8:49:24 AM ET J.P. Morgan Securities LONDON, October 26 ( - Analysts at JP Morgan reiterate their "overweight" rating on Bayer AG (BAY.ETR), while raising their estimates for the company. The 12-month target price has been raised from €70 to €73. In a research note published this morning, the analysts mention that there is a 60% probability of the company's Rivaroxaban product achieving peak sales of €5 billion. Bayer's share price is expected to be supported by the improved outlook for the Consumer Health division, oral contraceptives and Kogenate margins, the analysts say. The EPS estimates for 2007 and 2008 have been raised from €3.81 to €3.82 and from €4.19 to €4.21, respectively.
ariane: Bayer initiated with "outperform" Friday, September 14, 2007 10:21:29 AM ET Bear Stearns LONDON, September 14 ( - Analyst Richard Vosser of Bear Stearns reinitiates coverage of Bayer AG (BAY.ETR) with an "outperform" rating. The target price is set to €75. In a research note published this morning, the analyst mentions that the company's Healthcare business is expected to generate 18.9% EPS growth in 2007-2011 and is unlikely to reach an earnings trough up to 2015. Despite the high quality of the Healthcare business, Bayer's share price reflects the value of this business in-line with that of the European large-cap pharma peers, the analyst says. While Xarelto has the potential to become a multi-billion euro product over the next ten years, Nexavar may become a blockbuster in liver cancer, Bear Stearns adds.
ariane: Bayer "buy" Tuesday, September 04, 2007 7:19:03 AM ET Dresdner Kleinwort Wasser. LONDON, September 4 ( - Analyst Tero Weckroth of Dresdner Kleinwort maintains his "buy" rating on Bayer (BAY.ETR). The target price is set to €67. In a research note published this morning, the analyst mentions that the company's recent management roadshow was encouraging. Despite the 43% appreciation in Bayer's share price year-to-date, the current valuation of the company's stock is attractive, the analyst adds.
Bayer Ord share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20180226 01:55:42